Literature DB >> 3261712

Nature of immunological non-responsiveness to hepatitis B vaccine in healthy individuals.

S S Chiou1, K Yamauchi, T Nakanishi, H Obata.   

Abstract

This study was undertaken in order to analyse the immuno-regulatory mechanism of non-responsiveness to hepatitis B (HB) vaccine in healthy individuals. We have reported already that peripheral mononuclear cells (MNC) isolated from anti-HBs sero-positive subjects after booster injection are able to make anti-HBs in vitro by stimulation with pokeweed mitogen (PWM) plus HBsAg. In contrast, under the same conditions, non-responder (NR) MNC failed to produce anti-HBs in vitro, even after an additional injection, although an amount of immunoglobulin was synthesized corresponding with the responder controls. Co-culture experiments carried out with T-cell fractions (T) and non-T-cell fractions (NT) from NR and controls showed: (i) by Week 2 after the last vaccination, NT from NR could hardly be activated to produce anti-HBs; however, by Week 4 significant synthesis of anti-HBs was induced by the stimulation of responder T; (ii) in experiments using responder NT and T from NR, seven out of eight and five out of nine co-cultures were found to make anti-HBs by Weeks 2 and 4, respectively; (iii) T from NR, as well as their culture supernatants, specifically suppressed anti-HBs production of responder MNC, especially by Week 4 after the last vaccination. From these results, it is predicted that the early stage of non-responsiveness in NR is mainly due to a defect of the B-cell repertoire, while that of the late stage is caused by the existence of HBsAg-specific suppressor T cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3261712      PMCID: PMC1385071     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  27 in total

1.  Immunoregulation in humans: control of antitetanus toxoid antibody production after booster immunization.

Authors:  R H Stevens; A Saxon
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

2.  Suppression of hepatitis B antibody synthesis by factor made by T cells from chronic hepatitis B carriers.

Authors:  K Yamauchi; T Nakanishi; S S Chiou; H Obata
Journal:  Lancet       Date:  1988-02-13       Impact factor: 79.321

3.  A seroepidemiologic study of hepatitis B virus infection in Taiwan.

Authors:  D S Chen; J L Sung; M Y Lai
Journal:  Taiwan Yi Xue Hui Za Zhi       Date:  1978-12

4.  Histocompatibility requirements for T cell help in specific in vitro antibody responses to influenza virus by human blood lymphocytes.

Authors:  R E Callard; C M Smith
Journal:  Eur J Immunol       Date:  1981-03       Impact factor: 5.532

5.  Hepatitis B infection in physicians. Results of a nationwide seroepidemiologic survey.

Authors:  A E Denes; J L Smith; J E Maynard; I L Doto; K R Berquist; A J Finkel
Journal:  JAMA       Date:  1978-01-16       Impact factor: 56.272

6.  Production of potent anti-Australia antigen sera of high specificity and sensitivity in goats.

Authors:  G R Dreesman; F B Hollinger; R M McCombs; J L Melnick
Journal:  Infect Immun       Date:  1972-02       Impact factor: 3.441

7.  A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report.

Authors:  W Szmuness; C E Stevens; E A Zang; E J Harley; A Kellner
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

8.  Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States.

Authors:  W Szmuness; C E Stevens; E J Harley; E A Zang; W R Oleszko; D C William; R Sadovsky; J M Morrison; A Kellner
Journal:  N Engl J Med       Date:  1980-10-09       Impact factor: 91.245

9.  Functional analysis of two human T-cell subpopulations: help and suppression of B-cell responses by T cells bearing receptors for IgM or IgG.

Authors:  L Moretta; S R Webb; C E Grossi; P M Lydyard; M D Cooper
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

10.  In vitro antigen-induced, antigen-specific antibody production in man. Specific and polyclonal components, kinetics, and cellular requirements.

Authors:  H C Lane; D J Volkman; G Whalen; A S Fauci
Journal:  J Exp Med       Date:  1981-10-01       Impact factor: 14.307

View more
  5 in total

1.  The cellular basis for lack of antibody response to hepatitis B vaccine in humans.

Authors:  E Egea; A Iglesias; M Salazar; C Morimoto; M S Kruskall; Z Awdeh; S F Schlossman; C A Alper; E J Yunis
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

2.  T cell responses to hepatitis B surface antigen are detectable in non-vaccinated individuals.

Authors:  Martin R Weihrauch; Michael von Bergwelt-Baildon; Milos Kandic; Martin Weskott; Winfried Klamp; Joachim Rosler; Joachim L Schultze
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

3.  Effects of mitogens and lymphokines on the regulation of the immune response to HBs antigen in vitro.

Authors:  I Knöller; U J Hoffmann; H H Werchau; W König
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

4.  Enumeration of hepatitis B surface antigen-specific B lymphocytes in responder and non-responder normal individuals vaccinated with recombinant hepatitis B surface antigen.

Authors:  M A Shokrgozar; F Shokri
Journal:  Immunology       Date:  2001-09       Impact factor: 7.397

5.  The immune response to hepatitis B vaccine in humans: inheritance patterns in families.

Authors:  M S Kruskall; C A Alper; Z Awdeh; E J Yunis; D Marcus-Bagley
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.